Empagliflozin (Jardiance)

Key Messages

• CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses empagliflozin (Jardiance), 10 mg or 25 mg, orally administered film-coated tablets.
• Indication: Indicated in adults as an adjunct to standard-of-care therapy for the treatment of chronic heart failure.